Stay updated on Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.

Latest updates to the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoChange DetectedDifference0.2%
- Check23 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed information about a phase II trial for cabozantinib in treating osteosarcoma and Ewing sarcoma, while adding new identifiers and classifications related to these conditions.SummaryDifference52%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe page has been updated to include information on Soft Tissue Sarcoma while removing references to Osteosarcoma. Additionally, the revision number has been updated from v2.14.2 to v2.14.3.SummaryDifference0.1%
- Check45 days agoChange DetectedDifference0.2%
Stay in the know with updates to Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib for Relapsed Osteosarcoma/Ewing Sarcoma Clinical Trial page.